{"id":"human-immunoglobulin-intravenous","safety":{"commonSideEffects":[{"rate":"5-15%","effect":"Headache"},{"rate":"5-10%","effect":"Fever"},{"rate":"5-10%","effect":"Chills"},{"rate":"5-10%","effect":"Myalgia"},{"rate":"5-15%","effect":"Infusion site reactions"},{"rate":"2-5%","effect":"Nausea"},{"rate":"<1%","effect":"Thrombosis (rare)"},{"rate":"<1%","effect":"Aseptic meningitis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IVIG contains polyclonal immunoglobulins (primarily IgG) extracted from pooled human plasma that bind to pathogens, toxins, and autoimmune targets. It works through multiple mechanisms including opsonization, complement activation, Fc receptor engagement, and immune modulation via anti-inflammatory pathways. This provides immediate passive immunity and helps restore immune function in immunodeficient or dysregulated states.","oneSentence":"Human immunoglobulin intravenous (IVIG) provides passive immunity by delivering pooled antibodies from multiple human donors to neutralize pathogens and modulate immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:51.996Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary immunodeficiency disorders"},{"name":"Secondary immunodeficiency (e.g., in hematologic malignancies or post-transplant)"},{"name":"Autoimmune and inflammatory conditions (e.g., immune thrombocytopenia, Guillain-Barré syndrome)"},{"name":"Recurrent infections in immunocompromised patients"}]},"trialDetails":[{"nctId":"NCT07043725","phase":"PHASE3","title":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-09-15","conditions":"HER2-positive Breast Cancer","enrollment":544},{"nctId":"NCT03798860","phase":"","title":"Monitoring of Donor-specific Antibodies After Treatment With Immunoglobulins, Plasmapheresis and Rituximab in Lung Transplantation","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2018-10-01","conditions":"Lung Transplantation, Donor-specific Anti-human Leukocyte Antigen(HLA) Antibodies","enrollment":340},{"nctId":"NCT07360314","phase":"PHASE1","title":"Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-02-13","conditions":"Advanced Solid Tumors","enrollment":138},{"nctId":"NCT07047144","phase":"PHASE2","title":"A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy","status":"RECRUITING","sponsor":"Scholar Rock, Inc.","startDate":"2025-09-15","conditions":"Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2","enrollment":52},{"nctId":"NCT01842386","phase":"PHASE1","title":"Rituximab for Anti-cytokine Autoantibody-Associated Diseases","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-04-29","conditions":"Pulmonary Alveolar Proteinosis (PAP), Severe Mucocutaneous Candidiasis","enrollment":7},{"nctId":"NCT05929664","phase":"PHASE2","title":"Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-07-05","conditions":"Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma","enrollment":70},{"nctId":"NCT07053384","phase":"PHASE1","title":"A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2025-07-10","conditions":"HIV Infections","enrollment":107},{"nctId":"NCT02573896","phase":"PHASE1","title":"Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells","status":"ACTIVE_NOT_RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2019-01-14","conditions":"Neuroblastoma","enrollment":13},{"nctId":"NCT06827236","phase":"PHASE1, PHASE2","title":"A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-04-23","conditions":"Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer","enrollment":380},{"nctId":"NCT06430801","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-05","conditions":"Crohn's Disease","enrollment":1200},{"nctId":"NCT06188559","phase":"PHASE2","title":"A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2024-04-10","conditions":"Breast Cancer","enrollment":135},{"nctId":"NCT05537740","phase":"PHASE1","title":"A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2022-10-11","conditions":"Advanced Solid Tumors","enrollment":129},{"nctId":"NCT07169734","phase":"PHASE1, PHASE2","title":"A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors","status":"RECRUITING","sponsor":"Alentis Therapeutics AG","startDate":"2025-08-26","conditions":"Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer","enrollment":180},{"nctId":"NCT06795893","phase":"","title":"The Anifrolumab PRIM Program","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-07","conditions":"Systemic Lupus Erythematosus","enrollment":240},{"nctId":"NCT03596645","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-10-29","conditions":"Colitis, Ulcerative","enrollment":84},{"nctId":"NCT06233942","phase":"PHASE1","title":"Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2024-04-12","conditions":"Advanced Solid Tumor","enrollment":308},{"nctId":"NCT06585488","phase":"PHASE1","title":"A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification","status":"RECRUITING","sponsor":"BeiGene","startDate":"2024-11-26","conditions":"Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer","enrollment":514},{"nctId":"NCT06276491","phase":"PHASE1","title":"Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Xencor, Inc.","startDate":"2024-04-04","conditions":"Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor","enrollment":282},{"nctId":"NCT04077463","phase":"PHASE1","title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":701},{"nctId":"NCT06659029","phase":"","title":"Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-01","conditions":"Systemic Lupus Erythematosus","enrollment":442},{"nctId":"NCT04850456","phase":"","title":"Treatment Strategy of Human Gamma Globulin on the Therapy for Intensively Ill Children With Inflammatory Storm","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2024-10-01","conditions":"Critical Illness, Sepsis, Severe","enrollment":200},{"nctId":"NCT06508463","phase":"PHASE1","title":"Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-01-05","conditions":"Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified","enrollment":21},{"nctId":"NCT06052059","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-10-25","conditions":"Ulcerative Colitis","enrollment":1020},{"nctId":"NCT07059000","phase":"PHASE3","title":"A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)","status":"RECRUITING","sponsor":"Kedrion S.p.A.","startDate":"2025-08-13","conditions":"Chronic Primary Immune Thrombocytopenia (ITP)","enrollment":40},{"nctId":"NCT07186842","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-11-18","conditions":"Advanced Solid Cancers","enrollment":245},{"nctId":"NCT06752356","phase":"PHASE3","title":"A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"RECRUITING","sponsor":"Kedrion S.p.A.","startDate":"2026-04","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":161},{"nctId":"NCT05424822","phase":"PHASE1","title":"A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-08-18","conditions":"Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":167},{"nctId":"NCT06636071","phase":"PHASE3","title":"Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2024-10-25","conditions":"Osteogenesis Imperfecta","enrollment":6},{"nctId":"NCT05865990","phase":"PHASE2","title":"HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2023-11-24","conditions":"Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult","enrollment":63},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT07410039","phase":"PHASE4","title":"Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-02-01","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":200},{"nctId":"NCT02908906","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2016-11-21","conditions":"Neoplasms","enrollment":413},{"nctId":"NCT03399799","phase":"PHASE1","title":"Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2017-12-16","conditions":"Hematological Malignancies","enrollment":279},{"nctId":"NCT06598800","phase":"PHASE1","title":"Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeiGene","startDate":"2024-10-18","conditions":"Advanced Solid Tumor","enrollment":87},{"nctId":"NCT07070232","phase":"PHASE1, PHASE2","title":"A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-08-12","conditions":"Advanced Solid Tumor","enrollment":980},{"nctId":"NCT05655312","phase":"PHASE1, PHASE2","title":"MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma","status":"RECRUITING","sponsor":"Perspective Therapeutics","startDate":"2023-06-01","conditions":"Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV","enrollment":300},{"nctId":"NCT06048718","phase":"PHASE2","title":"T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2024-06-05","conditions":"Breast Cancer, Metastatic Breast Cancer","enrollment":28},{"nctId":"NCT07413939","phase":"PHASE2, PHASE3","title":"RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive","status":"NOT_YET_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-04-30","conditions":"HER2-positive Breast Cancer","enrollment":650},{"nctId":"NCT04736173","phase":"PHASE2","title":"Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2021-02-08","conditions":"Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer","enrollment":169},{"nctId":"NCT07455734","phase":"PHASE1, PHASE2","title":"Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"BioNTech SE","startDate":"2026-03","conditions":"Advanced Solid Tumor Cancer","enrollment":533},{"nctId":"NCT06253637","phase":"PHASE2","title":"Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2024-10-17","conditions":"T-Lymphocytic Leukemia, Acute","enrollment":31},{"nctId":"NCT03849651","phase":"PHASE2","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-01-31","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)","enrollment":69},{"nctId":"NCT06594068","phase":"PHASE4","title":"Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-16","conditions":"Systemic Lupus Erythematosus","enrollment":16},{"nctId":"NCT05579366","phase":"PHASE1, PHASE2","title":"Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)","status":"RECRUITING","sponsor":"Genmab","startDate":"2022-12-07","conditions":"High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma","enrollment":764},{"nctId":"NCT06747585","phase":"PHASE1, PHASE2","title":"A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors","status":"RECRUITING","sponsor":"Alentis Therapeutics AG","startDate":"2024-12-16","conditions":"Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma","enrollment":170},{"nctId":"NCT05967299","phase":"PHASE1","title":"Study of Intravenous ZMA001 in Healthy Subjects","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2023-11-27","conditions":"Pulmonary Arterial Hypertension PAH","enrollment":96},{"nctId":"NCT05180474","phase":"PHASE1, PHASE2","title":"GEN1047 for Solid Tumors - First in Human (FIH) Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2021-12-13","conditions":"Breast Cancer, Breast Neoplasms, Endometrial Cancer, Endometrial Neoplasm, Ovarian Cancer, Ovarian Neoplasms","enrollment":179},{"nctId":"NCT07223541","phase":"PHASE2","title":"Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2026-01-15","conditions":"Clear Cell Renal Cell Carcinoma","enrollment":72},{"nctId":"NCT06956690","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors","status":"RECRUITING","sponsor":"Hummingbird Bioscience","startDate":"2025-12-17","conditions":"Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer","enrollment":180},{"nctId":"NCT06759649","phase":"PHASE1","title":"A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"Compugen Ltd","startDate":"2025-01-07","conditions":"Neoplasm, Cancer, Malignant Tumors","enrollment":200},{"nctId":"NCT06239220","phase":"PHASE2","title":"PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC","status":"RECRUITING","sponsor":"Glenn J. Hanna","startDate":"2024-02-16","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer","enrollment":25},{"nctId":"NCT07435129","phase":"PHASE2","title":"Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD","status":"NOT_YET_RECRUITING","sponsor":"Scholar Rock, Inc.","startDate":"2026-08","conditions":"Facioscapulohumeral Muscular Dystrophy, FSHD","enrollment":60},{"nctId":"NCT05832034","phase":"PHASE2, PHASE3","title":"Add-on Intravenous Immunoglobulins in Early Myositis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-09-13","conditions":"Inflammatory Myopathy, Idiopathic, Dermatomyositis, Antisynthetase Syndrome","enrollment":44},{"nctId":"NCT05662228","phase":"PHASE2","title":"Therapies for Down Syndrome Regression Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-06-29","conditions":"Down Syndrome, Regression","enrollment":66},{"nctId":"NCT05768854","phase":"PHASE3","title":"Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2023-06-14","conditions":"Osteogenesis Imperfecta","enrollment":69},{"nctId":"NCT07431775","phase":"","title":"Saphnelo Use in Females of Child-bearing Potential","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-10-01","conditions":"Systemic Lupus Erythematosus","enrollment":26000000},{"nctId":"NCT05593094","phase":"PHASE1, PHASE2","title":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-09-03","conditions":"Advanced Solid Tumors, HER2-positive Breast Cancer","enrollment":210},{"nctId":"NCT05125809","phase":"PHASE2, PHASE3","title":"Setrusumab vs Placebo for Osteogenesis Imperfecta","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2022-02-21","conditions":"Osteogenesis Imperfecta","enrollment":183},{"nctId":"NCT06599697","phase":"PHASE2","title":"The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-10-27","conditions":"Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy","enrollment":12},{"nctId":"NCT07431281","phase":"PHASE3","title":"Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-03","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer","enrollment":2130},{"nctId":"NCT05113251","phase":"PHASE3","title":"Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-25","conditions":"Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer","enrollment":927},{"nctId":"NCT07181681","phase":"PHASE1","title":"A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-11-10","conditions":"Solid Tumors, Advanced Solid Tumor","enrollment":63},{"nctId":"NCT06422520","phase":"PHASE1","title":"A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2024-07-08","conditions":"Advanced Solid Tumor","enrollment":120},{"nctId":"NCT06959706","phase":"PHASE1","title":"Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Tagworks Pharmaceuticals BV","startDate":"2025-05-07","conditions":"Advanced Solid Tumors","enrollment":50},{"nctId":"NCT06565078","phase":"","title":"A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-02-17","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":100},{"nctId":"NCT05527184","phase":"PHASE1","title":"First in Human Study of IMGN151 in Recurrent Gynaecological Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-01-11","conditions":"Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma","enrollment":256},{"nctId":"NCT04868877","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merus B.V.","startDate":"2021-04-28","conditions":"Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma","enrollment":194},{"nctId":"NCT07337525","phase":"PHASE1","title":"A First in Human Study of PLT012 in Participants With Solid Tumor Cancers","status":"RECRUITING","sponsor":"Pilatus Biosciences Inc","startDate":"2026-02-13","conditions":"Advanced Malignant Solid Tumor, Solid Tumor Cancer","enrollment":36},{"nctId":"NCT07238075","phase":"PHASE1","title":"ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers","status":"RECRUITING","sponsor":"Adcytherix SAS","startDate":"2026-02-14","conditions":"Advanced Malignancy, Advanced Solid Cancers, Metastatic Solid Tumors","enrollment":290},{"nctId":"NCT07414836","phase":"PHASE1","title":"A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"BeOne Medicines","startDate":"2026-04-30","conditions":"Advanced Solid Tumor","enrollment":84},{"nctId":"NCT03504241","phase":"PHASE1","title":"Tolerance by Engaging Antigen During Cellular Homeostasis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-30","conditions":"Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient","enrollment":8},{"nctId":"NCT05092347","phase":"PHASE1, PHASE2","title":"A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-08-02","conditions":"Chronic Kidney Disease (CKD)","enrollment":56},{"nctId":"NCT04930432","phase":"PHASE1, PHASE2","title":"Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors","status":"RECRUITING","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2021-09-24","conditions":"Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer","enrollment":400},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT04639986","phase":"PHASE3","title":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2020-11-23","conditions":"Metastatic Breast Cancer","enrollment":331},{"nctId":"NCT03569553","phase":"","title":"A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients","status":"NOT_YET_RECRUITING","sponsor":"Emergent BioSolutions","startDate":"2027-05-30","conditions":"Inhalational Anthrax","enrollment":100},{"nctId":"NCT03569514","phase":"","title":"Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax","status":"NOT_YET_RECRUITING","sponsor":"Emergent BioSolutions","startDate":"2026-11-30","conditions":"Anthrax","enrollment":10},{"nctId":"NCT07388758","phase":"PHASE2","title":"Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":37},{"nctId":"NCT06350318","phase":"PHASE2","title":"Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-04-19","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma, B-Cell Lymphoma","enrollment":43},{"nctId":"NCT06564038","phase":"PHASE1, PHASE2","title":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-01-30","conditions":"Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma","enrollment":276},{"nctId":"NCT06143371","phase":"PHASE1","title":"A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis.","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2023-08-21","conditions":"Healthy, Plaque Psoriasis","enrollment":80},{"nctId":"NCT05755035","phase":"PHASE2, PHASE3","title":"A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-10-24","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":65},{"nctId":"NCT04626635","phase":"PHASE1, PHASE2","title":"A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-12-21","conditions":"Advanced Solid Tumors","enrollment":933},{"nctId":"NCT06340568","phase":"PHASE3","title":"A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-06-10","conditions":"Endometrial Cancer","enrollment":480},{"nctId":"NCT05856890","phase":"PHASE1","title":"HepB mAb19 in Individuals With Chronic Hepatitis B Infection","status":"RECRUITING","sponsor":"Rockefeller University","startDate":"2023-08-07","conditions":"Hepatitis b Virus, Hepatitis B","enrollment":37},{"nctId":"NCT06809114","phase":"PHASE1","title":"FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Axcynsis Therapeutics Pte Ltd","startDate":"2026-01-14","conditions":"Solid Tumor","enrollment":83},{"nctId":"NCT05952804","phase":"PHASE2","title":"IVIG for Infection Prevention After CAR-T-Cell Therapy","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-06-10","conditions":"Hematologic Malignancies","enrollment":150},{"nctId":"NCT07214987","phase":"PHASE2","title":"PDT For Induction Therapy For Head And Neck Cancer","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-03-09","conditions":"Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer","enrollment":26},{"nctId":"NCT07009899","phase":"PHASE2","title":"BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-03-01","conditions":"Multiple Myeloma","enrollment":34},{"nctId":"NCT07377253","phase":"PHASE1","title":"First-in-Human Study Testing a New Antibody Treatment for Tick-Borne Encephalitis in Healthy Volunteers.","status":"NOT_YET_RECRUITING","sponsor":"Giuseppe Pantaleo","startDate":"2026-01-01","conditions":"The Tick-borne Encephalitis Virus (TBEV)","enrollment":18},{"nctId":"NCT06840119","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers","status":"RECRUITING","sponsor":"Immunocore Ltd","startDate":"2024-01-10","conditions":"Cancer, HLA-A*02:01-positive","enrollment":600},{"nctId":"NCT06445075","phase":"PHASE2","title":"Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese","status":"COMPLETED","sponsor":"Scholar Rock, Inc.","startDate":"2024-05-21","conditions":"Overweight and Obesity","enrollment":102},{"nctId":"NCT05156320","phase":"PHASE3","title":"Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam","status":"COMPLETED","sponsor":"Scholar Rock, Inc.","startDate":"2022-04-14","conditions":"Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2","enrollment":188},{"nctId":"NCT04827979","phase":"PHASE1, PHASE2","title":"Daratumumab and Belatacept for Desensitization","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-11-01","conditions":"Highly Sensitized Prospective Kidney Transplant Recipients","enrollment":19},{"nctId":"NCT07221513","phase":"PHASE2","title":"Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension","status":"RECRUITING","sponsor":"Salubris Biotherapeutics Inc","startDate":"2025-12-15","conditions":"HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension","enrollment":30},{"nctId":"NCT07278336","phase":"PHASE1","title":"A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-11-27","conditions":"Ovarian Cancer","enrollment":207},{"nctId":"NCT06747351","phase":"PHASE3","title":"A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-05-06","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","enrollment":59},{"nctId":"NCT06962631","phase":"PHASE3","title":"V-IMMUNE® for Immune Thrombocytopenia","status":"RECRUITING","sponsor":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","startDate":"2025-07-18","conditions":"Immune Thrombocytopenia (ITP)","enrollment":31},{"nctId":"NCT06954441","phase":"PHASE3","title":"V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency","status":"RECRUITING","sponsor":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","startDate":"2025-08-15","conditions":"Immunodeficiencies, Primary Immunodeficiencies (PID), Agammaglobulinemia","enrollment":50},{"nctId":"NCT02609776","phase":"PHASE1","title":"Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05-24","conditions":"Non-Small-Cell Lung Cancer","enrollment":751}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":56,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GC5107A (IV-Globulin SN Inj. 10%)"],"phase":"phase_3","status":"active","brandName":"Human immunoglobulin intravenous","genericName":"Human immunoglobulin intravenous","companyName":"Green Cross Corporation","companyId":"green-cross-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Human immunoglobulin intravenous (IVIG) provides passive immunity by delivering pooled antibodies from multiple human donors to neutralize pathogens and modulate immune responses. Used for Primary immunodeficiency disorders, Secondary immunodeficiency (e.g., in hematologic malignancies or post-transplant), Autoimmune and inflammatory conditions (e.g., immune thrombocytopenia, Guillain-Barré syndrome).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}